Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Terrascend Corp T.TSND

Alternate Symbol(s): TSNDF

Healthcare Cannabis

TerrAscend Corp. is a Canada-based cannabis company. The Company has vertically integrated licensed operations in Pennsylvania, New Jersey, Maryland, Michigan and California through TerrAscend Growth Corp. and retail operations in Canada through TerrAscend Canada Inc. (TerrAscend). TerrAscend operates The Apothecarium, Gage and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing product selection to both the medical and legal adult-use markets. The Company a variety of product types including flower, vaporizable, concentrates, topicals, tinctures, and edibles. The Company owns or licenses several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections.

TSX:TSND - Post by User

Terrascend Corp

<< Previous

Bullboard Posts

Next >>

Post by proneon Dec 21, 2020 8:16am

145 Views

Post# 32151168

News for the Canopy Group .... Legalization coming ....

Acreage Holdings

@AcreageCannabis

Dec 18

 												We are excited to have Peter Caldini join #AcreageHoldings as CEO. He brings a proven track record of improving operational efficiencies, strengthening brand equity, & creating shareholder value. Details here: https://bit.ly/2J4lhcw $ACRG $ACRG.AU $ACRGF

Canopy Growth

@CanopyGrowth

Dec 18

 												In this episode of #UnderTheCanopy we are joined by John Walsh, Director for Drug Policy and the Andes, Washington Office on Latin America. John's work focuses on the need to reassess drug policy goals globally & reforming drug treaties.